COMPASS Pathways Phase 3 interim results — what does this actually mean for access?
83 replies · News & Current Events
The COMPASS Pathways Phase 3 interim data is out and being described as 'positive' and 'meeting primary endpoints.' I want to cut through the press release language. What does it actually show, what are the limitations, and what does FDA approval realistically mean for patient access vs. what people are hoping it means?
I'm asking because I see a lot of 'psilocybin is almost legal!' framing that seems to misunderstand what pharmaceutical approval actually does and doesn't create.
The data is genuinely significant. 35-40% response rate (vs ~15% for control) in treatment-resistant depression — a population for whom most treatments have failed — is clinically meaningful. The durability signal (60-65% of initial responders maintaining at 12 weeks) addresses the primary Phase 2b concern. This is real evidence of real efficacy.
What it doesn't create if approved: recreational access, easy access, cheap access, or decriminalization. COMP360 would be a Schedule II or III drug administered in licensed clinical settings by trained staff. Think IV ketamine — legal, but requiring a clinic, a prescriber, and significant out-of-pocket cost. It would likely be years before insurance coverage reaches most patients even after approval.
The approval timeline matters: NDA submission planned late 2026, FDA review 12-18 months, so earliest approval scenario is Q4 2027 or 2028. Advisory committee meeting will be public and fascinating — the blinding problem in psychedelic trials will get real scrutiny. Don't plan your life around 2026 as the year psilocybin becomes medically available.
80 more replies — forum posting coming soon.